Extremely careful observation of preventive measures seems essential to eradicate HCV transmission in Background. Hepatitis viruses have become one of the main infectious problems in patients on maintenance haemodialysis units. haemodialysis. The aim of this study was to prospectKey words: blood transfusion; genotypes; HCV; ively investigate the incidence of de novo hepatitis C haemodialysis; nosocomial; transmission virus ( HCV ) infection in a haemodialysis unit and to identify factors currently involved in HCV transmission to haemodialysis patients.
tive and HCV-RNA negative patients who started long-term haemodialysis were followed for a mean After the introduction of measures aimed to control period of 36 months (range 18-56 ). Liver tests and the spread of hepatitis B virus infection in dialysis anti-HCV were performed at 6-month intervals.
units, it became clear that dialysis patients were at Factors that might be implicated in HCV transmission, increased risk of exposure to the etiologic agent of such as blood transfusions, sexual habits, surgery and parenterally transmitted non-A, non-B (C ) hepatitis. other invasive procedures, were recorded. HCV The prevalence of HCV infection in haemodialysis markers were re-examined in transfused blood and the patients varies markedly from country to country and HCV genotype was investigated in seroconverters to from one center to another and ranges between 5% in anti-HCV and in patients with previous HCV infection North European countries and in the US to more than who were treated in the vicinity of those who 20% in the Mediterranean area [1] . The relevance of seroconverted.
HCV infection in patients on haemodialysis is related Results. Eight patients (7%) seroconverted to antito the development of serious liver disease, particularly HCV and seven of them became HCV-RNA positive.
after renal transplantation [2] [3] [4] . HCV markers, including HCV-RNA, were negative in Blood transfusion and the length of time on the blood transfused to seroconverters. No differences haemodialysis were the main factors involved in HCV between seroconverters and non-seroconverters were transmission to haemodialysis patients in the past [5 ] . found in other risk factors not directly related to However, despite screening of blood products for HCV haemodialysis. The investigation of HCV genotype and the wide use of erythropoietin, which reduces suggested that HCV transmission was not restricted to blood transfusion requirements, some patients still patients treated in the vicinity of previously HCV become infected by HCV during haemodialysis. Thus, infected patients. Occasional failure to observe strict mechanisms other than blood transfusion do possibly measures of asepsis was detected in the haemodialysis operate in HCV transmission in this setting. unit and this was the only factor that might be
The analysis of genomic sequences of HCV isolates incriminating.
from around the world has demonstrated that these Conclusions. HCV acquisition in patients on haemodiasequences can be classified into distinct genotypes [6 ] . lysis is currently not related to blood transfusion, and
The existence of several genetic groups of HCV has nosocomial transmission within the haemodialysis unit clinical relevance and the molecular analysis of HCV seems to be the main mechanism of HCV infection.
genomes has been extensively used in epidemiological surveys.
involved in HCV transmission to haemodialysis Features of the haemodialysis unit patients.
In our Institution HBsAg and anti-HIV negative patients on long-term haemodialysis are treated in two different areas.
Patients with serious complications associated to chronic renal failure are dialysed in an in-hospital area and patients
Patients and methods
with uncomplicated chronic renal failure are treated in an area located outside the Hospital. Thirty one of our patients
Patients
were treated in the in-hospital and 83 in the out-hospital area. The prevalence of anti-HCV among patients receiving One hundred and twenty-two consecutive patients who treatment in these areas at the beginning of the study was entered into a long term haemodialysis program for end-28% and 24%, respectively. stage renal failure from January 1991 to October 1993 in a Eight physicians and 41 nurses were directly involved in single Institution were enrolled in this study. All patients patients' care. All personnel of our haemodialysis unit are were negative for HBsAg, anti-HCV and anti-HIV antibodies regularly tested (once a year) for liver enzymes and antiand for HCV RNA in serum at the time of starting HCV. In our study anti-HCV was positive in two nurses. haemodialysis.
One of them had a positive HCV-RNA and elevated ALT Patients were followed while on haemodialysis until whereas ALT was normal and HCV-RNA negative in the September 1995. Eight patients were excluded because death other. (two cases), renal transplantation (four cases) or change of Hemodialysis machines in use in our Center were 2008E residence (two cases) occurred less than 6 months after (Fresenius, Schweinfurt, Germany) and Monitral S (Hospal, enrollment. Thus, the final analysis included 114 patients. Medolla, Italy). Dialyzers (cellulose acetate, Miro-Nova 140, The main characteristics of these patients are shown in Althin Medical, Miami, FLD, USA; polysulfone, Bellco, Table 1 . The mean follow-up was 36 months, ranging from Mirandola, Italy; polyacrylonitrile, Filtrat 10 AN69, Hospal, 18-56 months.
Meyzieu, France) are not reused. The dialysate circuit is Routine liver tests (including serum alanine aminotransfer-disinfected with sodium hypochlorite after each individual ase [ALT ], aspartate aminotransferase, gamma glutamyl session. transpeptidase, alkaline phosphatase and bilirubin) and antiUniversal measures of asepsis (changing of gloves after HCV (second or third generation ELISA) were examined each patient manipulation, avoiding sharing of articles every 6 months. Whenever hepatitis was suspected, the among patients), and disinfection of environmental surfaces interval between these measurements was shortened and and machines are routinely done in our haemodialysis units. HCV-RNA was determined. In patients who presented seroconversion to anti-HCV positive, HCV RNA and HCV Blood products genotype were investigated. At the end of the study, HCV-RNA was also investigated in 50 additional anti-HCV negaBlood and blood products used for transfusion were obtained tive patients.
from volunteer donors and screened for anti-HCV with a Factors that could be involved in HCV transmission such second or third generation ELISA. All blood products adminas transfusion of blood or blood products, diagnostic or istered to patients who developed seroconversion to antitherapeutic invasive procedures, intravenous drug abuse, HCV positive were re-examined for anti-HCV by third tattooing and sexual habits were recorded. In order to generation ELISA and tested for HCV RNA. A stored evaluate the role of patient to patient transmission, HCVfrozen sample of each transfusion held in our blood bank RNA and HCV genotype were investigated in anti-HCV was used for this examination. positive patients who received treatment regularly on the same haemodialysis machine or in the beds adjacent to patients who seroconverted to anti-HCV during the follow-Laboratory methods up.
All nurses were individually interviewed to evaluate their Anti-HCV antibodies were tested with second or third generaadherence to universal measures of asepsis.
tion ELISA (the last starting in June 1993) (Ortho Diagnostics, Systems, Raritan, New York, USA). Serum HCV-RNA was tested by reverse transcription nested PCR. RNA extraction was performed with the acid guanidinium Table 1 . Characteristics of 114 patients on haemodialysis included thiocyanate-phenol-chloroform method from 180 ml of serum in the study [7] . RNA was precipitated with isopropanol and rinsed with 70% cold ethanol. cDNA was synthesized from RNA with the 5∞ non-coding region (5∞NCR) of HCV were used for Diabetic nephropathy 9 (8%) amplification [ 8] . All experiments included appropriate posit- lines [9 ] . HCV genotype was determined by restriction fragment length polymorphism ( RFLP) analysis of the 5∞NCR, accordaM: male ing to Davidson et al. [10 ] . Briefly, PCR products from the bESRF: end-stage renal failure Quantitative variables are expressed as mean±standard deviation 5∞NCR were digested with MvaI/HinfI and with RsaI/HaeII and electrophoresed in a 4% Metaphor agarose gel (FMC ally significant differences between seroconverters and Bioproducts, Rockland, USA). Major HCV genotypes were non-seroconverters (36±9 vs. 35±12 months, respectdetermined according to established RFLP patterns. In order ively). Regarding other risk factors for HCV acquisito determine HCV subtype, samples containing type 1 HCV tion in patients who seroconverted to anti-HCV, one were digested with BstUI to differentiate type 1a from 1b; patient was a sexually promiscuous heterosexual man samples containing type 2 and type 3 were digested with and two other patients underwent invasive procedures ScrFI to differentiate types 2a from 2b, and 3a from 3b, (Figure 1 An interview of all nurses who were directly involved in patients' care disclosed some breaks from standard infection-control practices. Twenty out of 41 nurses Results admitted to not changing their gloves when urgently required to assist a patient bleeding from the arterioSeroconversion to anti-HCV venous fistula. In addition, almost all nurses remembered situations when they had failed to change their Seroconversion to anti-HCV was observed in eight gloves due to an urgent adjustment of a haemodialysis patients (7%). Three of them were treated in the machine. in-hospital area and five in the out-hospital area. None of these patients seroconverted to anti-HCV positive during the first year of haemodialysis. The mean Study of HCV genotypes age of seroconverters (61±18 years) and non-In order to evaluate the possible role of patient to seroconverters (57±15 years) was similar. A mild patient transmission, the HCV genotype found in each elevation of aminotransferase values preceded anti-patient who became infected during the study was HCV seroconversion for about three months in seven compared with the genotype found in each previously cases, and persisted for more than one year in five. known anti-HCV positive patient who received regular Increased gamma glutamyl transpeptidase levels were haemodialysis on the same machine or who slept in an observed in six of the eight patients and remained adjacent bed ( Table 2) . Infection with the same HCV abnormal for more than one year in five patients. HCV genotype was detected in two cases (case 1 and 6 ), RNA was detected in seven cases.
with a different genotype in two cases (cases 2 and 3 ) Mild abnormalities of liver tests were detected occa-and was partially coinciding in one case (case 4 ). No sionally during follow-up in 20 non-seroconverters evidence of HCV infection was found in patients ( 19%). However, the presence of these abnormalities dialysed in the same or adjacent beds in two further was transient ( lasting less than three months) and cases (cases 5 and 7 ). HCV-RNA was not detected in any of these patients. None of them had clinical evidence of liver disease.
HCV-RNA was also not detected when tested in 50 Discussion anti-HCV negative patients at the end of the follow-up.
Hepatitis viruses have become one of the principal Risk factors for HCV acquisition
infectious problems in patients on haemodialysis. Although remarkably variable, the prevalence of HCV Analysis of potential risk factors for HCV transmission infection in haemodialysis patients is consistently higher did not show differences between patients who than in blood donors from the same area, suggesting developed seroconversion to anti-HCV and those who did not. Five of the eight patients (62%) who seroconverted to anti-HCV received blood or blood products during the follow-up prior to seroconversion ( Figure 1 ). The proportion of non-seroconverters who received transfusions (50%) was statistically not different. The mean number of blood units transfused to seroconverters and non-seroconverters did not differ ( 7.8±7.5 vs. 8.6±6.3, respectively). A total of 39 stored frozen samples corresponding to all blood products transfused to anti-HCV seroconverters were re-examined. Neither anti-HCV antibodies nor HCV RNA were demonstrated in any of these blood was submitted to a surgical procedure and another patient was a products.
promiscuous heterosexual male. (**) One patient was submitted to an invasive diagnostic procedure.
Mean time on haemodialysis did not show statistic- that these patients are a high risk population [1] . HCV to anti-HCV seroconverters clearly exclude this mechanism of transmission in our haemodialysis unit. infection has a marked tendency to become chronic, causing slow progression to hepatic cirrhosis and liver Despite the use of blood screened for HCV, cases of HCV infection still occur among haemodialysis failure in many patients [11 ] . However, the long term prognosis of HCV infection in haemodialysis patients patients, indicating that mechanisms other than blood transfusion may operate [19] [20] [21] . One possible has not been yet fully elucidated. Most HCV-infected patients do not present clinical or biochemical evidence explanation is that HCV infection was acquired outside the haemodialysis unit. However, a well recognized of liver disease, but liver biopsies demonstrate that histological liver damage is relatively common in these risk factor, such as intravenous drug abuse, was not present in our patients and no data supporting HCV patients [12 ] . In addition, HCV infection may have serious consequences when these patients are submitted transmission by surgery or other invasive diagnostic procedures were obtained in the current study. to renal transplantation because immunosuppression may accelerate the course of HCV infection [3 ] . More Therefore, acquisition of HCV infection outside the haemodialysis unit was also unlikely. effective measures to prevent HCV infection and a better definition of HCV transmission mechanisms in Whereas there is still no general agreement, cumulative evidence suggests that nosocomial transmission haemodialysis patients are clearly necessary.
The incidence of seroconversion for anti-HCV in within the haemodialysis unit plays a key role in HCV transmission to these patients [22] [23] [24] [25] . Several studies our haemodialysis unit stays within the range of other reported studies [13, 14] and may be considered as have shown that the incidence of HCV infection in patients treated with continuous ambulatory peritoneal relatively low. Regarding the possibility of underestimating the incidence of de novo HCV infection using an dialysis or home-haemodialysis is clearly lower than in those treated in haemodialysis units [26 ] . anti-HCV ELISA, third generation assays for anti-HCV have been shown to be very sensitive in patients Passage of HCV through dialysis membranes is theoretically not possible because the estimated diaon haemodialysis [15] [16] [17] . In addition, in the current study we did not detect HCV-RNA in a group of anti-meter of the virus is much larger than the pore size of membranes [27] . Although disruption of the membrane HCV negative patients tested at the end of the follow-up. integrity could theoretically permit the passage of the virus to the blood compartment, in our study, all The mechanisms responsible for HCV transmission to haemodialysis patients are not entirely clear. Trans-dialyzer membranes were discarded after a single use and haemodialysis machines and tubing were carefully fusion with blood non-screened for HCV was strongly involved in the past, but this route does not appear to washed with sodium hypochlorite immediately after each individual session. Thus, transmission of HCV is be currently incriminated. Prospective studies have demonstrated that HCV related hepatitis is extremely rare probably not associated with the haemodialysis procedure itself, if it is performed with strict application of in recipients of blood screened by second generation ELISA [18] . In the current study, blood transfusion universal precautions [28, 29] .
Environmental factors may be more important. might theoretically be responsible of HCV transmission in five of the eight patients who developed HCV infec-Outbreaks of HCV infection have been reported in haemodialysis units in association with poor measures tion during their time on haemodialysis. However, the amount of blood transfused to patients who did not of asepsis, whereas strict adherence to infection control procedures has led to a decline in the incidence of the acquire HCV infection was not different. In addition, the re-testing of anti-HCV and HCV-RNA by PCR in infection [25, 30] . In our unit, standard infectioncontrol practices were routinely observed. Change of the transfused blood represents a conclusive way of excluding the remote possibility of a postransfusional gloves after each patient manipulation, avoiding sharing of articles among patients, and disinfection of HCV hepatitis. In fact, the negative results of both ELISA and PCR assays in all blood products transfused environmental surfaces and machines were routinely genotypes and subtypes of hepatitis C virus using RFLP of done. However, a meticulous interview of all nurses sequences amplified from the 5∞ non-coding region. J Gen Virol disclosed that breaks of this stringent policy might 1995; 76: 1197-1204 have occurred. Regarding the high prevalence of HCV 11. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, 
